BLIS Technologies Ltd

Founded on the research of Professor John Tagg at the University of Otago, New Zealand, and the discovery of oral probiotic strains BLIS K12 and BLIS M18, BLIS Technologies' strains are backed by more than 30 years of research, over 70 clinical trials and an IP-protected supply chain. The company offers partners both ingredient and finished products across health areas including immunity, teeth and gums, mouth, throat and oral health.